Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083424 | 0.89 | KMT2A (0.52) | MTTPALDH1A1NPC1RAB9ATDP1 | |
| SCHEMBL6792699 | 0.83 | MTTP (0.58) | MTTPALDH1A1MAPTKMT2A | |
| SCHEMBL6794433 | 0.82 | ABCG2 (0.70) | MTTPALDH1A1NPC1RAB9AABCG2 | |
| SCHEMBL6222007 | 0.82 | MTTP (0.61) | MTTPALDH1A1 | |
| SCHEMBL14031525 | 0.80 | KCNMA1 (0.66) | MTTPALDH1A1NPC1RAB9ATDP1 | |
| SCHEMBL6261203 | 0.80 | MTTP (0.62) | MTTPALDH1A1KMT2A | |
| SCHEMBL6816754 | 0.79 | MAPT (0.71) | ALDH1A1NPC1RAB9ATDP1MAPT | |
| SCHEMBL24460395 | 0.77 | KCNMA1 (0.78) | ALDH1A1NPC1RAB9ATDP1MAPT | |
| SCHEMBL1548208 | 0.76 | KMT2A (0.68) | ALDH1A1NPC1RAB9ATDP1MAPT | |
| SCHEMBL24460413 | 0.75 | RORC (0.65) | ALDH1A1NPC1RAB9ATDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MTTP 363/4885ALDH1A1 1427/4885NPC1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.